Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $22.50 Consensus Target Price from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $22.50.

CLBT has been the topic of several research analyst reports. Wall Street Zen downgraded Cellebrite DI from a “hold” rating to a “sell” rating in a research note on Saturday. Bank of America boosted their target price on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Needham & Company LLC lowered their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, November 13th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CLBT. Voss Capital LP increased its position in shares of Cellebrite DI by 18.9% during the fourth quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock worth $145,142,000 after acquiring an additional 1,277,300 shares in the last quarter. Pertento Partners LLP lifted its position in Cellebrite DI by 28.2% in the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after acquiring an additional 1,311,109 shares in the last quarter. Invesco Ltd. boosted its stake in Cellebrite DI by 0.8% in the 4th quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock worth $101,026,000 after purchasing an additional 43,041 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its stake in Cellebrite DI by 17.1% in the 2nd quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock worth $62,608,000 after purchasing an additional 570,000 shares during the period. Finally, Granahan Investment Management LLC increased its holdings in Cellebrite DI by 16.3% during the 4th quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after purchasing an additional 427,719 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT opened at $14.70 on Friday. Cellebrite DI has a 52-week low of $11.76 and a 52-week high of $20.86. The stock has a market cap of $3.67 billion, a P/E ratio of 47.42, a P/E/G ratio of 2.29 and a beta of 1.30. The firm has a 50 day moving average price of $15.48 and a 200 day moving average price of $16.94.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting the consensus estimate of $0.14. The company had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. Analysts predict that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.